Annual Short Term Debt
$15.63 M
-$217.00 K-1.37%
December 31, 2023
Summary
- As of February 7, 2025, CRSP annual short term debt is $15.63 million, with the most recent change of -$217.00 thousand (-1.37%) on December 31, 2023.
- During the last 3 years, CRSP annual short term debt has risen by +$4.26 million (+37.52%).
- CRSP annual short term debt is now -1.37% below its all-time high of $15.84 million, reached on December 31, 2022.
Performance
CRSP Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Short Term Debt
$16.88 M
+$432.00 K+2.63%
September 30, 2024
Summary
- As of February 7, 2025, CRSP quarterly short term debt is $16.88 million, with the most recent change of +$432.00 thousand (+2.63%) on September 30, 2024.
- Over the past year, CRSP quarterly short term debt has increased by +$1.26 million (+8.05%).
- CRSP quarterly short term debt is now at all-time high.
Performance
CRSP Quarterly Short Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Short Term Debt Formula
Short-Term Debt = Current Portion of Long-Term Debt + Short-Term Loans + Commercial Paper + Other Short-Term Borrowings
CRSP Short Term Debt Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -1.4% | +8.1% |
3 y3 years | +37.5% | +33.6% |
5 y5 years | +100.0% | +251.4% |
CRSP Short Term Debt Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -1.4% | +28.5% | at high | +104.2% |
5 y | 5-year | -1.4% | +84.1% | at high | +104.2% |
alltime | all time | -1.4% | -100.0% | at high | -100.0% |
CRISPR Therapeutics AG Short Term Debt History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $16.88 M(+2.6%) |
Jun 2024 | - | $16.45 M(+2.9%) |
Mar 2024 | - | $15.99 M(+2.3%) |
Dec 2023 | $15.63 M(-1.4%) | $15.63 M(+4.2%) |
Sep 2023 | - | $15.00 M(+1.1%) |
Jun 2023 | - | $14.83 M(-5.6%) |
Mar 2023 | - | $15.72 M(-0.8%) |
Dec 2022 | $15.84 M(+30.3%) | $15.84 M(+40.7%) |
Sep 2022 | - | $11.26 M(+36.2%) |
Jun 2022 | - | $8.27 M(-25.4%) |
Mar 2022 | - | $11.08 M(-8.9%) |
Dec 2021 | $12.16 M | $12.16 M(-3.8%) |
Date | Annual | Quarterly |
---|---|---|
Sep 2021 | - | $12.64 M(-20.4%) |
Jun 2021 | - | $15.88 M(+31.6%) |
Mar 2021 | - | $12.06 M(+6.2%) |
Dec 2020 | $11.36 M(+33.8%) | $11.36 M(+6.8%) |
Sep 2020 | - | $10.64 M(+7.4%) |
Jun 2020 | - | $9.91 M(+10.0%) |
Mar 2020 | - | $9.01 M(+6.1%) |
Dec 2019 | $8.49 M(>+9900.0%) | $8.49 M(+76.7%) |
Sep 2019 | - | $4.80 M(-1.5%) |
Jun 2019 | - | $4.88 M(-0.4%) |
Mar 2019 | - | $4.90 M(>+9900.0%) |
Dec 2018 | $0.00 | $0.00 |
FAQ
- What is CRISPR Therapeutics AG annual short term debt?
- What is the all time high annual short term debt for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual short term debt year-on-year change?
- What is CRISPR Therapeutics AG quarterly short term debt?
- What is the all time high quarterly short term debt for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly short term debt year-on-year change?
What is CRISPR Therapeutics AG annual short term debt?
The current annual short term debt of CRSP is $15.63 M
What is the all time high annual short term debt for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual short term debt is $15.84 M
What is CRISPR Therapeutics AG annual short term debt year-on-year change?
Over the past year, CRSP annual short term debt has changed by -$217.00 K (-1.37%)
What is CRISPR Therapeutics AG quarterly short term debt?
The current quarterly short term debt of CRSP is $16.88 M
What is the all time high quarterly short term debt for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly short term debt is $16.88 M
What is CRISPR Therapeutics AG quarterly short term debt year-on-year change?
Over the past year, CRSP quarterly short term debt has changed by +$1.26 M (+8.05%)